Entrada Therapeutics (NASDAQ:TRDA) Major Shareholder Ventures L.P. 5Am Sells 10,494 Shares

Key Points

• Major shareholder Ventures L.P. 5Am sold 10,494 Entrada Therapeutics shares at an average price of $7.00, generating $73,458. The shareholder retained 2,836,098 shares after the transaction.
• TRDA shares rose 1.2% to $6.95, but the company reported a quarterly loss of $1.01 per share, missing estimates, while revenue of $0.90 million fell well short of the $2.32 million consensus.
• Institutional investors own 86.39% of Entrada Therapeutics. Analysts’ average rating is “Hold,” with a consensus price target of $17.50, though recent target changes and rating actions were mixed.

Entrada Therapeutics, Inc. (NASDAQ:TRDA - Get Free Report) major shareholder Ventures L.P. 5Am sold 10,494 shares of the stock in a transaction on Thursday, August 6th. The shares were sold at an average price of $7.00, for a total transaction of $73,458.00. Following the completion of the sale, the insider directly owned 2,836,098 shares in the company, valued at approximately $19,852,686. This represents a 0.37% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Major shareholders that own 10% or more of a company's stock are required to disclose their sales and purchases with the SEC.

Entrada Therapeutics Trading Up 1.2%

Shares of TRDA stock traded up $0.08 during trading hours on Monday, reaching $6.95. 411,770 shares of the stock were exchanged, compared to its average volume of 464,800. The firm has a market capitalization of $270.63 million, a price-to-earnings ratio of -1.76 and a beta of -0.26. Entrada Therapeutics, Inc. has a 12-month low of $4.93 and a 12-month high of $16.45. The company's 50-day moving average price is $6.86 and its 200-day moving average price is $9.68.

Entrada Therapeutics (NASDAQ:TRDA - Get Free Report) last announced its quarterly earnings data on Wednesday, August 5th. The company reported ($1.01) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.97) by ($0.04). Entrada Therapeutics had a negative return on equity of 57.61% and a negative net margin of 3,537.73%.The firm had revenue of $0.90 million during the quarter, compared to the consensus estimate of $2.32 million. On average, sell-side analysts expect that Entrada Therapeutics, Inc. will post -4.07 EPS for the current year.

Institutional Investors Weigh In On Entrada Therapeutics

A number of institutional investors and hedge funds have recently bought and sold shares of TRDA. Baker BROS. Advisors LP grew its holdings in Entrada Therapeutics by 4.3% during the 4th quarter. Baker BROS. Advisors LP now owns 5,072,730 shares of the company's stock worth $52,148,000 after acquiring an additional 206,911 shares in the last quarter. JPMorgan Chase & Co. raised its holdings in shares of Entrada Therapeutics by 735.0% in the 3rd quarter. JPMorgan Chase & Co. now owns 133,878 shares of the company's stock valued at $776,000 after purchasing an additional 117,844 shares in the last quarter. Allspring Global Investments Holdings LLC raised its holdings in shares of Entrada Therapeutics by 9.8% in the 4th quarter. Allspring Global Investments Holdings LLC now owns 17,495 shares of the company's stock valued at $176,000 after purchasing an additional 1,560 shares in the last quarter. BlackRock Inc. purchased a new stake in shares of Entrada Therapeutics in the 2nd quarter worth approximately $19,013,000. Finally, Deutsche Bank AG purchased a new stake in shares of Entrada Therapeutics in the 2nd quarter worth approximately $195,000. 86.39% of the stock is owned by institutional investors.

Analysts Set New Price Targets

A number of research firms recently issued reports on TRDA. Roth Capital set a $10.00 price objective on Entrada Therapeutics in a report on Friday, May 8th. Guggenheim decreased their target price on Entrada Therapeutics from $20.00 to $17.00 and set a "buy" rating for the company in a research report on Monday, June 8th. Weiss Ratings lowered shares of Entrada Therapeutics from a "sell (d)" rating to a "sell (d-)" rating in a research note on Thursday, June 11th. Finally, HC Wainwright downgraded shares of Entrada Therapeutics from a "buy" rating to a "neutral" rating in a research note on Friday, May 8th. Three equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company's stock. Based on data from MarketBeat, the stock currently has an average rating of "Hold" and a consensus price target of $17.50.

Entrada Therapeutics Company Profile

Entrada Therapeutics NASDAQ: TRDA is a clinical-stage biotechnology company focused on enabling the development of protein-based therapeutics that can cross cell membranes and engage intracellular targets. Using its proprietary cell-penetrating miniature protein (CPMP) platform and intracellular targeting of proteins (iTOP) delivery technology, Entrada aims to expand the range of diseases addressable by large-molecule drugs.

The company's pipeline includes programs in rare and serious diseases where conventional biologics have limited intracellular activity.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source